He Jie Tang in the treatment of chronic hepatitis B patients

doi:10.3748/wjg.v11.i42.6638

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 11, Issue 42

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2817)

All Articles published online

The chart showing PDF series, HTML series, Tables (1-4) series.

Item

Count

PDF

325

HTML

2332

Tables (1-4)

160

Sum=2817

Nov 14, 2005 (publication date) through Nov 8, 2024

Times Cited of This Article

Times Cited (7)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Viral Hepatitis

World J Gastroenterol. Nov 14, 2005; 11(42): 6638-6643
Published online Nov 14, 2005. doi: 10.3748/wjg.v11.i42.6638

Table 1 Levels of ALT, AST, TB, and HBV-DNA before and after the treatment (mean±SD)

		n	ALT (U/L)	AST (U/L)	TB (μmol/L)	HBV-DNA (copy/mL)
Group III		20	21.52±8.90	15.56±7.65	11.75±5.71	<1 000
Group I	Pre-T	50	232.52±12.25	139.65±9.62	43.35±5.86	(1.62±0.81)×10^8.31
	Post-T	50	33.26±9.35^b	35.18±8.26^b	19.95±5.12^b	(9.25±1.90)×10^5.02a
Group II	Pre-T	35	225.70±11.61	135.45±9.21	41.45±5.85	(1.47±0.65)×10^8.22
Post-T		35	30.86±8.95^b	65.68±8.82^b	29.55±546^b	(8.26±2.20)×10^7.62

Pre-T: before treatment; Post-T: after treatment; ^aP＜0.05 vs before treatment in the same group;

^bP＜0.01 vs before treatment in the same group.

Table 2 T lymphocyte subsets before and after the treatment (mean±SD)

		n	CD₃ (%)	CD₄ (%)	CD₈(%)	CD₄/CD₈
Group III		20	68.10±9.25	39.27±8.70	30.96±6.82	1.70±0.72
Group I	Pre-T	50	65.55±8.22	35.06±5.38^b	34.80±4.36^b	1.10±0.35^b
	Post-T	50	67.35±8.85	37.60±8.52^a	31.95±5.61^a	1.31±0.42^a
Group II	Pre-T	35	65.86±9.21	35.15±6.01^b	35.10±6.56^b	1.07±0.46^b
	Post-T	35	66.71±9.56	35.92±8.55	34.66±6.25	1.12±0.36

Pre-T: before treatment; Post-T: after treatment;

^bP<0.01 vs group III ;

^aP＜0.05 vs before treatment in the same group.

Table 3 Serum levels of TNF-α, sIL-2R, and IL-8 as well as NK activity before and after the treatment (mean±SD)

		n	TNF-a (mg/L)	sIL-2R (kU/L)	IL-8 (μg/L)	NK (%)
Group III		20	0.58±0.23	310.0±30.7	0.72±0.2	59.65±7.5
Group I	Pre-T	50	18.8±8.9^b	390.9±12.0^b	2.42±0.8^b	43.12±6.5^b
	Post-T	50	10.5±6.8^a	310.22±8.9^a	1.12±0.5^a	52.90±7.0^a
Group II	Pre-T	35	19.0±7.2^b	395.7±16.5^b	2.45±0.8^b	43.02±6.8^b
	Post-T	35	15.62±7.9	355.6±9.5	1.80±0.7	46.54±6.9

αPre-T: before treatment; Post-T: after treatment;

^aP＜0.05 vs before treatment in the same group;

^bP<0.01 vs group III.

Table 4 T lymphocyte subsets in responders and non-responders of group I before and after the treatment (mean±SD)

		n	CD₃ (%)	CD₄ (%)	CD₈ (%)	NK (%)
Responders	Pre-T	7	66.02±8.86	35.10±4.76^b	34.92±4.36^b	43.52±7.1^b
	Post-T	7	67.80±9.11	38.85±8.85^a	30.15±5.82^a	55.60±8.2^a
Non-responders	Pre-T	43	65.50±9.08	34.92±6.30^b	34.77±6.56^b	42.93±6.7 ^b
	Post-T	43	66.09±9.35	35.99±8.70	34.25±5.52	45.60±6.5
Group III		20	68.10±9.25	39.27±8.70	30.96±6.82	59.65±7.5

^aP<0.05 vs before treatment in the same group;

^bP<0.01 vs group III.

Citation: Chen ZX, Zhang SJ, Lao SX, Hu HT, Zhang CY, Guan SH, Gu YL. He Jie Tang in the treatment of chronic hepatitis B patients. World J Gastroenterol 2005; 11(42): 6638-6643
URL: https://www.wjgnet.com/1007-9327/full/v11/i42/6638.htm
DOI: https://dx.doi.org/10.3748/wjg.v11.i42.6638